Valneva (VALN): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
3 concentrated managers hold it (+1 vs last quarter) with a median weight of 0.3%.
Who owns Valneva?
Valneva trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Caisse DES Depots ET Consignations, 9.3% (13D/A filed May 12, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Frazier Life Sciences Management (2.3 million ADRs), Vivo Capital (763,199 ADRs) and General American Investors (354,361 ADRs).
Which institutions hold the most Valneva shares?
Per Form 13F filings as of Jun 30, 2026, in ADRs:
- 1. Frazier Life Sciences Management: 2.3 million ADRs
- 2. Vivo Capital: 763,199 ADRs
- 3. General American Investors: 354,361 ADRs
- 4. Millennium Management: 135,223 ADRs
- 5. Wells Fargo: 77,214 ADRs
- 6. Morgan Stanley: 56,217 ADRs
- 7. Ironwood Investment Management: 45,064 ADRs
- 8. Citadel Advisors: 20,294 ADRs
- 9. XTX Topco: 15,178 ADRs
- 10. VSM Wealth Advisory: 10,000 ADRs
Sources:13D/A by Caisse DES Depots ET Consignations (May 12, 2026) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Change in managers (2 → 3): 1 opened · 0 exited = +1
Net flow in the quarter: +$4.0M (+763 K shares) · bought $4.0M and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
The set of concentrated managers changed between quarters: with the set as it was then, 1 held it last quarter (the chart point); with today's set, 2 (the base for the change).
Concentrated managers holding it
- Frazier Life Sciences Management$12.0M0.3%
- Vivo CapitalNew$4.0M0.4%+0.3 pp
- General American Investors$1.9M0.1%
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of VALN (all 13F filers)
- Frazier Life Sciences Managementconcentrated2.3 MInvestment firm0
- Vivo Capitalconcentrated763 KInvestment firm+763 K
- General American Investorsconcentrated354 KInvestment firm0
- Millennium Management135 KQuant or multi-manager+135 K
- Wells Fargo77 KBank or trading desk−815
- Morgan Stanley56 KBank or trading desk+9,292
- Ironwood Investment Management45 KType not verified+20 K
- Citadel Advisors20 KQuant or multi-manager+20 K
- XTX Topco15 KType not verified+15 K
- VSM Wealth Advisory10 KWealth adviser0
- Frazier Life Sciences Managementconcentrated
- Shares
- 2.3 M
- Change
- 0
See more
- Type
- Investment firm
- Value
- $12.0M
- Vivo Capitalconcentrated
- Shares
- 763 K
- Change
- +763 K
See more
- Type
- Investment firm
- Value
- $4.0M
- General American Investorsconcentrated
- Shares
- 354 K
- Change
- 0
See more
- Type
- Investment firm
- Value
- $1.9M
- Shares
- 135 K
- Change
- +135 K
See more
- Type
- Quant or multi-manager
- Value
- $707K
- Shares
- 77 K
- Change
- −815
See more
- Type
- Bank or trading desk
- Value
- $404K
- Shares
- 56 K
- Change
- +9,292
See more
- Type
- Bank or trading desk
- Value
- $294K
- Ironwood Investment Management
- Shares
- 45 K
- Change
- +20 K
See more
- Type
- Type not verified
- Value
- $236K
- Shares
- 20 K
- Change
- +20 K
See more
- Type
- Quant or multi-manager
- Value
- $106K
- Shares
- 15 K
- Change
- +15 K
See more
- Type
- Type not verified
- Value
- $79.4K
- VSM Wealth Advisory
- Shares
- 10 K
- Change
- 0
See more
- Type
- Wealth adviser
- Value
- $52.3K
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Insiders (Form 4)
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- Frazier Life Sciences Public Fund3.6%(fell below 5%)13Gfiling ↗Event: May 5, 2026 · filed: May 12, 2026
- Caisse DES Depots ET Consignations9.3%13D · amendmentfiling ↗Event: May 5, 2026 · filed: May 12, 2026
- Caisse DES Depots ET Consignations10.5%13D · amendmentfiling ↗Event: Feb 27, 2026 · filed: Mar 10, 2026
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers